{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:34:51Z","timestamp":1792852491853,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":1418,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1186\/s13613-022-01059-9","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T19:04:02Z","timestamp":1664478242000},"page":"90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-6415","authenticated-orcid":false,"given":"Paul","family":"Chabert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Provoost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Dupieux-Chabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bitker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Goutelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1186\/s13613-022-01059-9_bb0010","unstructured":"European Centre for Disease Prevention and Control (ECDC). Surveillance of antimicrobial resistance in Europe 2018. 2019."},{"issue":"3","key":"10.1186\/s13613-022-01059-9_bb0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jhin.2017.11.022","article-title":"Carriage of ESBL-producing Enterobacteriaceae in French hospitals: the PORTABLSE study","volume":"98","author":"Pilmis","year":"2018","journal-title":"J Hosp Infect"},{"issue":"4","key":"10.1186\/s13613-022-01059-9_bb0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/CCM.0000000000002253","article-title":"ICU acquisition rate, risk factors, and clinical significance of digestive tract colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis","volume":"45","author":"Detsis","year":"2017","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1186\/s13613-022-01059-9_bb0025","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jhin.2013.04.018","article-title":"Risk factors for developing ESBL E coli: can clinicians predict infection in patients with prior colonization?","volume":"84","author":"Goulenok","year":"2013","journal-title":"J Hosp Infect"},{"issue":"1","key":"10.1186\/s13613-022-01059-9_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/antibiotics10010015","article-title":"Long-term carbapenems antimicrobial stewardship program","volume":"10","author":"Garc\u00eda-Rodr\u00edguez","year":"2020","journal-title":"Antibiotics"},{"issue":"8","key":"10.1186\/s13613-022-01059-9_bb0035","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1093\/cid\/ciz1205","article-title":"Is Piperacillin-Tazobactam effective for the treatment of pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing organisms?","volume":"71","author":"Sharara","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-022-01059-9_bb0040","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1086\/499405","article-title":"Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms","volume":"42","author":"Niederman","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1186\/s13613-022-01059-9_bb0045","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-015-3853-7","article-title":"Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric)","volume":"41","author":"Bretonni\u00e8re","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-022-01059-9_bb0050","unstructured":"HA de Sant\u00e9. Antibioth\u00e9rapie des infections \u00e0 ent\u00e9robact\u00e9ries et \u00e0 Pseudomonas aeruginosa chez l\u2019adulte: place des carbap\u00e9n\u00e8mes et de leurs alternatives. 2019;1\u201325."},{"issue":"1","key":"10.1186\/s13613-022-01059-9_bb0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1128\/AAC.11.1.84","article-title":"Cefoxitin activity against multiply antibiotic-resistant Klebsiella pneumoniae in vitro","volume":"11","author":"Jackson","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1186\/s13613-022-01059-9_bb0060","first-page":"181","article-title":"Treatment options for extended-spectrum beta-lactamase-producers","volume":"190","author":"Essack","year":"2000","journal-title":"FEMS Microbiol Lett"},{"issue":"3","key":"10.1186\/s13613-022-01059-9_bb0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.medmal.2012.01.004","article-title":"C\u00e9foxitine et BLSE","volume":"42","author":"Boyer","year":"2012","journal-title":"M\u00e9d et Maladies Infect"},{"issue":"1","key":"10.1186\/s13613-022-01059-9_bb0070","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/clinids\/1.1.233","article-title":"Cefoxitin: an overview of clinical studies in the United States","volume":"1","author":"Neu","year":"1979","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-022-01059-9_bb0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2014.08.018","article-title":"Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"29","author":"Asakura","year":"2014","journal-title":"Inter J Infect Dis"},{"key":"10.1186\/s13613-022-01059-9_bb0080","article-title":"Efficacy of cefoxitin for the treatment of urinary tract infection due to extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates","volume":"6","author":"Senard","year":"2019","journal-title":"Ther Adv Infect"},{"issue":"4","key":"10.1186\/s13613-022-01059-9_bb0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.medmal.2016.04.008","article-title":"Cefoxitin: an alternative to carbapenems in urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"46","author":"Mambie","year":"2016","journal-title":"M\u00e9d et Maladies Infect"},{"issue":"11","key":"10.1186\/s13613-022-01059-9_bb0090","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/23744235.2015.1062133","article-title":"Cefoxitin as a carbapenem-sparing antibiotic for infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"47","author":"Kern\u00e9is","year":"2015","journal-title":"Infect Dis"},{"issue":"3","key":"10.1186\/s13613-022-01059-9_bb0095","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1128\/AAC.11.3.427","article-title":"Cefoxitin: clinical evaluation in thirty-eight patients","volume":"11","author":"Heseltine","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1186\/s13613-022-01059-9_bb0100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12879-016-1770-1","article-title":"Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems","volume":"16","author":"Fukuchi","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"9","key":"10.1186\/s13613-022-01059-9_bb0105","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.00701-15","article-title":"Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-\u03b2-lactamase-producing Escherichia coli bacteremia","volume":"59","author":"Matsumura","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1186\/s13613-022-01059-9_bb0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0002-9610(88)80219-8","article-title":"Comparative effectiveness and safety of cefotetan and cefoxitin as prophylactic agents in patients undergoing abdominal or vaginal hysterectomy","volume":"155","author":"Berkeley","year":"1988","journal-title":"Am J Surg"},{"issue":"2","key":"10.1186\/s13613-022-01059-9_bb0115","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1128\/jcm.35.2.508-510.1997","article-title":"Study of an outbreak of cefoxitin-resistant Klebsiella pneumoniae in a general hospital","volume":"35","author":"Gazouli","year":"1997","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1186\/s13613-022-01059-9_bb0120","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1590\/S1517-83822013000200015","article-title":"Carbapenem and cefoxitin resistance of Klebsiella pneumoniae strains associated with porin OmpK36 loss and DHA-1 \u03b2-lactamase production","volume":"44","author":"Shi","year":"2013","journal-title":"Braz J Microbiol"},{"key":"10.1186\/s13613-022-01059-9_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/S0255-0857(21)02706-7","article-title":"Cefoxitin resistance mediated by loss of a porin in clinical strains of Klebsiella pneumoniae and Escherichia coli","author":"Ananthan","year":"2005","journal-title":"Indian J Medical Microbiol"},{"key":"10.1186\/s13613-022-01059-9_bb0130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1469-0691.2007.01860.x","article-title":"Extended-spectrum \u03b2-lactamases and the permeability barrier","volume":"14","author":"Mart\u00ednez-Mart\u00ednez","year":"2008","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1186\/s13613-022-01059-9_bb0135","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1186\/s13613-022-01059-9_bb0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13613-017-0237-x","article-title":"Relation between presence of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in systematic rectal swabs and respiratory tract specimens in ICU patients","volume":"7","author":"Carbonne","year":"2017","journal-title":"Ann Intensive Care"},{"key":"10.1186\/s13613-022-01059-9_bb0145","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"issue":"24","key":"10.1186\/s13613-022-01059-9_bb0150","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","article-title":"A new simplified acute physiology score (SAPS II) based on a European\/North American multicenter study","volume":"270","author":"Le Gall","year":"1993","journal-title":"JAMA"},{"issue":"8","key":"10.1186\/s13613-022-01059-9_bb0155","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1186\/s13613-022-01059-9_bb0160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"5","key":"10.1186\/s13613-022-01059-9_bb0165","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.medmal.2018.03.005","article-title":"Practice guidelines for the management of adult community-acquired urinary tract infections","volume":"48","author":"Caron","year":"2018","journal-title":"Med Mal Infect"},{"issue":"10","key":"10.1186\/s13613-022-01059-9_bb0170","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.rmr.2016.07.007","article-title":"Description et place des techniques bact\u00e9riologiques dans la prise en charge des infections pulmonaires","volume":"34","author":"Dahyot","year":"2017","journal-title":"Rev Mal Respir"},{"key":"10.1186\/s13613-022-01059-9_bb0175","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie. Enterobacterales. CASFM\/EUCAST; 2021."},{"issue":"6","key":"10.1186\/s13613-022-01059-9_bb0180","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Pharmacokinetic\/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC)","year":"2020","journal-title":"Intensiv Care Med"},{"issue":"3","key":"10.1186\/s13613-022-01059-9_bb0185","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10096-016-2832-4","article-title":"High target attainment for \u03b2-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied","volume":"36","author":"Woksepp","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"S1","key":"10.1186\/s13613-022-01059-9_bb0190","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1002\/jhm.869","article-title":"Use of pharmacodynamic principles to inform \u03b2-lactam dosing: \u201cS\u201d does not always mean success","volume":"6","author":"Lodise","year":"2011","journal-title":"J Hosp Med"},{"issue":"1","key":"10.1186\/s13613-022-01059-9_bb0195","first-page":"1","article-title":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, And Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"7","author":"Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1186\/s13613-022-01059-9_bb0200","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v064.i04","article-title":"fitdistrplus: an R package for fitting distributions","author":"Delignette-Muller","year":"2015","journal-title":"J Stat Soft"},{"issue":"4","key":"10.1186\/s13613-022-01059-9_bb0205","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R","volume":"34","author":"Neely","year":"2012","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1186\/s13613-022-01059-9_bb0210","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00228-011-1206-1","article-title":"Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery","volume":"68","author":"Isla","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1186\/s13613-022-01059-9_bb0215","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/jac\/dkl381","article-title":"Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates","volume":"58","author":"Lee","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1186\/s13613-022-01059-9_bb0220","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.ijid.2012.09.010","article-title":"The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"17","author":"Doi","year":"2013","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1186\/s13613-022-01059-9_bb0225","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijantimicag.2019.02.001","article-title":"Use of non-carbapenem antibiotics to treat severe extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae infections in intensive care unit patients","volume":"53","author":"Luyt","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1186\/s13613-022-01059-9_bb0230","first-page":"33","article-title":"Cefoxitin sodium compatibility with intravenous infusions and additives","volume":"36","author":"O\u2019Brien","year":"1979","journal-title":"Am J Hosp Pharm"},{"issue":"1","key":"10.1186\/s13613-022-01059-9_bb0235","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/clinids\/1.1.90","article-title":"Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins","volume":"1","author":"Schrogie","year":"1979","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1186\/s13613-022-01059-9_bb0240","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1128\/AAC.20.6.741","article-title":"Cefoxitin pharmacokinetics: relation to three different renal clearance studies in patients with various degrees of renal insufficiency","volume":"20","author":"Kampf","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1186\/s13613-022-01059-9_bb0245","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1128\/AAC.02509-14","article-title":"Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-\u03b2-lactamase-producing Escherichia coli","volume":"58","author":"Guet-Revillet","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1186\/s13613-022-01059-9_bb0250","first-page":"816","article-title":"Hemolytic anemia and pancytopenia induced by cefoxitin","volume":"17","author":"DeTorres","year":"1983","journal-title":"Drug Intell Clin Pharm"},{"issue":"3","key":"10.1186\/s13613-022-01059-9_bb0255","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1128\/AAC.26.3.343","article-title":"Alterations in human fecal flora, including ingrowth of clostridium difficile, related to cefoxitin therapy","volume":"26","author":"Mulligan","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1186\/s13613-022-01059-9_bb0260","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1128\/AAC.19.1.18","article-title":"Evaluation of cefoxitin nephrotoxicity in experimentally induced renal failure","volume":"19","author":"Ormrod","year":"1981","journal-title":"Antimicrob Agent Chemother"},{"issue":"9","key":"10.1186\/s13613-022-01059-9_bb0265","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1164\/rccm.200905-0704OC","article-title":"Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients","volume":"180","author":"Jeon","year":"2009","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-022-01059-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13613-022-01059-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025006569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025006569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-022-01059-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:35:40Z","timestamp":1776670540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025006569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2110582025006569"],"URL":"https:\/\/doi.org\/10.1186\/s13613-022-01059-9","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-022-01059-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Author(s) 2022. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"90"}}